Overview
Nor-metanephrine, also known as normetadrenaline, is an inactive metabolite of the catecholamine norepinephrine. It is formed through O-methylation of norepinephrine by the enzyme catechol O-methyltransferase and is produced mainly in the adrenal medulla and sympathetic postganglionic neurons. Nor-metanephrine is not biologically active but is continuously generated within chromaffin cells and sympathetic nerves, making it a stable and reliable biochemical marker. It is present in plasma and urine in both free and conjugated forms, with the majority excreted in urine as conjugates. Measurement of nor metanephrine plays a central role in screening and diagnosis of catecholamine-secreting tumors, particularly pheochromocytoma and paraganglioma.
Symptoms
Nor-metanephrine itself produces symptoms. Clinical features arise from excessive catecholamine secretion by underlying tumors. Typical symptoms include episodic or sustained hypertension, severe headaches, excessive sweating, palpitations, tachycardia, pallor, and anxiety. These manifestations are often described as the classic five Ps of pheochromocytoma, namely pressure, pain, perspiration, palpitation, and pallor. Symptoms may be episodic and can worsen during stress, anesthesia, surgery, or physical exertion.
Causes
Elevated nor-metanephrine levels occur due to increased production and metabolism of norepinephrine, most commonly from catecholamine-secreting tumors such as pheochromocytoma and paraganglioma. Neuroblastoma may also cause increased levels. Non-tumor-related causes include acute stress, hypoglycemia, trauma, pain, surgery, excessive exercise, and certain medications that alter catecholamine metabolism. Reduced nor metanephrine levels may be seen in conditions such as dopamine beta hydroxylase deficiency, deficiency of catechol O methyltransferase, Parkinson’s disease, multiple system atrophy, autonomic failure, diabetic autonomic neuropathy, and adrenal insufficiency.
Risk Factors
Risk factors prompting nor metanephrine testing include episodic headaches, unexplained hypertension, tachycardia, diaphoresis, family history of pheochromocytoma, multiple endocrine neoplasia syndromes, and incidentally detected adrenal masses. Patients with equivocal catecholamine elevations or unexplained haemodynamic instability are also at risk. Interpretation can be affected by renal disease, as well as by medications such as antidepressants, monoamine oxidase inhibitors, sympathomimetics, levodopa, beta blockers, clonidine, and methyldopa. Improper patient preparation, stress, or incorrect sampling position may lead to false positive results.
Prevention
There are no preventive measures to avoid elevated normetanephrine levels caused by tumors or intrinsic disease processes. Prevention in a diagnostic context focuses on reducing false positive results and ensuring accurate interpretation. Patients should follow strict pre-analytical preparation, including fasting, avoidance of alcohol, caffeine, tobacco, strenuous exercise, and interfering medications prior to testing. Blood samples should be collected with the patient in a fully recumbent position after adequate rest, and urine samples should be properly refrigerated during collection. Appropriate testing, careful sample handling, and correlation with clinical findings support early diagnosis, timely intervention, and effective management of catecholamine-related disorders.
